The ringing never stops. For roughly 750 million people worldwide, according to a 2022 systematic review in JAMA Neurology, tinnitus is a constant companion: a hiss, a buzz, a tone that exists only inside the head. Treatments remain limited, partly because the biological machinery behind the phantom sound has been difficult to pin down. Now, a study from Oregon Health & Science University, led by Zheng-Quan Tang and Laurence Bhatt Trussell of the Oregon Hearing Research Center, offers one of the most direct clues yet. Their paper, “Serotonergic modulation of dorsal cochlear nucleus neurons and tinnitus-related behavior” (Tang and Trussell, Proceedings of the National Academy of Sciences, 2025; doi:10.1073/pnas.2421427122), links tinnitus-like behavior in mice to serotonin, the neurotransmitter most often associated with mood regulation.
Using a technique called optogenetics, the researchers controlled serotonin-producing neurons in the dorsal raphe nucleus, the brainstem’s largest cluster of serotonin cells and a structure that broadcasts chemical signals across much of the brain. When those neurons were switched on with light, mice showed increased tinnitus-like behavioral responses. When the same neurons were silenced, those responses dropped. “The bidirectional effect was striking,” Tang said in an OHSU summary of the research. The fact that the effect ran in both directions moves serotonin from a mere bystander in tinnitus research to an active participant.
A chemical chain from mood center to ear circuit
The new findings do not exist in isolation. They slot into a growing body of work tracing how chemical imbalances in the auditory brainstem can generate phantom sound perception.
The dorsal cochlear nucleus, or DCN, is one of the brain’s first relay stations for processing sound. Earlier mouse research established that animals displaying tinnitus-like behavior had hyperactive DCN neurons driven by weakened GABAergic inhibition, the brain’s primary braking system for electrical activity. Separate anatomical studies have traced serotonin-carrying nerve fibers from the dorsal and median raphe nuclei directly into the DCN, confirming a physical route for serotonin to reach auditory circuits. And independent recordings in awake mice found that applying serotonin to DCN neurons produced a net increase in excitability mediated by the 5-HT2A receptor subtype.
Stitch those results together and a plausible sequence emerges. Serotonin released from the raphe nuclei reaches the DCN, amplifies neuronal firing through 5-HT2A receptors, and tilts the balance between excitation and inhibition toward runaway activity. The brain reads that activity as sound, even when silence surrounds the ear. The OHSU optogenetic experiment adds causal weight to the sequence: turning the serotonin signal on or off directly changed the animals’ behavior.
Genetic evidence from a separate line of research reinforces the broader framework. A large-scale analysis of UK Biobank data, published in Nature Communications in January 2024, found that tinnitus and hearing loss have distinct genetic architectures. The two conditions are not simply different stages of the same disorder. That study highlighted how mismatches between inhibitory GABA networks and excitatory glutamate networks along the auditory pathway could explain why some people develop tinnitus independently of measurable hearing damage. The serotonin findings from OHSU identify yet another chemical lever capable of shifting that excitatory-inhibitory balance.
What remains uncertain
Every piece of serotonin-tinnitus evidence published so far comes from mouse models. Whether the identical circuit operates in the human brainstem has not been confirmed through direct neuroimaging or postmortem tissue analysis. Mice cannot describe what they hear; researchers infer tinnitus-like states from behavioral proxies such as gap-detection tests, which measure how an animal reacts to brief silences embedded in background noise. These proxies are well validated in auditory neuroscience, but they remain indirect stand-ins for a deeply subjective experience.
The 5-HT2A receptor flagged in the DCN studies is the same receptor targeted by several existing psychiatric medications, including certain atypical antipsychotics and psychedelic-assisted therapies under investigation for depression. That overlap raises an obvious therapeutic question. Yet as of May 2026, no large-scale clinical trials specifically designed to test serotonin-modulating drugs as tinnitus treatments have reported results. A handful of smaller or older studies have examined SSRIs in tinnitus patients with mixed outcomes, but none were built around the brainstem circuit the OHSU work describes. The distance between a mouse optogenetic experiment and a prescription that helps patients remains wide.
Multiple chemical systems also appear to be involved. Separate animal research has linked salicylate-induced tinnitus to suppressed GABAergic activity in the thalamic reticular nucleus and to altered patterns of brain-wave oscillations between the thalamus and cortex, with endocannabinoid signaling playing a contributing role. How that thalamic pathway interacts with the brainstem serotonin circuit has not been mapped. No single study has yet woven these threads into a unified model of tinnitus.
Then there is the puzzle of individual variability. Even among people with similar degrees of hearing loss, only a fraction develop chronic tinnitus. The UK Biobank genetics work suggests that inherited differences in neurotransmitter systems, synaptic plasticity, or neural resilience could influence who is vulnerable. Serotonin may be one component of that vulnerability profile, but it is unlikely to be the sole driver. Noise exposure history, chronic stress, and certain medications probably interact with these biological predispositions in ways researchers are still working to untangle.
What the evidence can and cannot support
The OHSU optogenetic study sits at the top of the evidence hierarchy for this story. Direct causal manipulation of a defined set of neurons, with a measurable behavioral change in both directions, is a higher standard than correlation. The earlier DCN hyperactivity work used electrophysiology to record real changes in neuronal firing rates, and the in vivo serotonin application study measured real-time shifts in how DCN neurons responded to sound, pinpointing a specific receptor. Each experiment tested a concrete prediction and reported quantifiable outcomes.
The UK Biobank paper operates at a different scale: population genetics rather than single-neuron recordings. It does not test serotonin directly, but its conclusion that excitatory-inhibitory imbalances along the auditory pathway can drive tinnitus independently of hearing damage is consistent with the mouse data. Readers should treat it as supporting context, not direct proof of the serotonin mechanism.
Anatomical tract-tracing studies that mapped serotonin projections from the raphe nuclei to the cochlear nucleus provide an important bridge. They demonstrate that the brain’s mood-related centers have direct physical access to early auditory processing hubs, making it biologically plausible that shifts in emotional state or systemic serotonin levels could spill into how sound is perceived. On their own, though, these maps do not reveal whether serotonin’s net effect is to increase or decrease tinnitus risk; that inference requires combining them with the functional experiments.
Serotonin as a target: promise and distance from the clinic
For people living with tinnitus, the practical message is cautious. The new work does not justify changing prescriptions for serotonin-related drugs based on tinnitus concerns alone, nor does it validate off-label use of psychiatric medications as tinnitus treatments. What it does provide is a sharper set of targets for future human studies: specific brainstem nuclei, a named receptor subtype, and a circuit motif that can be probed with modern neuroimaging tools.
Carefully designed clinical trials, ideally pairing brain imaging with genetic profiling, will be needed to determine whether modulating serotonin can safely and meaningfully quiet the phantom sounds that millions of people endure. The mouse experiments do not close that gap, but they narrow it in a way that years of observational research could not. Tinnitus, it is becoming clearer, is not just an ear problem. It is a brain-wide network phenomenon, and serotonin now looks like one of its key switching stations.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
